Inhibrx, Inc. (NASDAQ:INBX – Get Free Report) CEO Mark Lappe purchased 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was acquired at an average cost of $15.81 per share, for a total transaction of $316,200.00. Following the transaction, the chief executive officer now owns 165,000 shares in the company, valued at approximately $2,608,650. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Mark Lappe also recently made the following trade(s):
- On Thursday, August 29th, Mark Lappe acquired 10,000 shares of Inhibrx stock. The stock was bought at an average cost of $14.03 per share, with a total value of $140,300.00.
Inhibrx Trading Up 9.5 %
NASDAQ:INBX traded up $1.39 on Tuesday, hitting $15.95. The stock had a trading volume of 290,343 shares, compared to its average volume of 183,656. Inhibrx, Inc. has a 1 year low of $10.80 and a 1 year high of $18.95. The firm’s fifty day simple moving average is $13.33 and its two-hundred day simple moving average is $25.17.
Hedge Funds Weigh In On Inhibrx
Several institutional investors have recently bought and sold shares of INBX. AJOVista LLC bought a new stake in shares of Inhibrx in the fourth quarter valued at approximately $26,000. Charles Schwab Investment Management Inc. raised its stake in shares of Inhibrx by 8.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 229,866 shares of the company’s stock valued at $8,735,000 after purchasing an additional 17,762 shares during the period. E Fund Management Co. Ltd. purchased a new stake in Inhibrx during the 4th quarter worth about $209,000. Quadrant Capital Group LLC purchased a new position in Inhibrx during the 4th quarter valued at about $26,000. Finally, HCR Wealth Advisors bought a new stake in shares of Inhibrx during the fourth quarter valued at about $239,000. Hedge funds and other institutional investors own 82.46% of the company’s stock.
Analysts Set New Price Targets
Separately, JMP Securities started coverage on Inhibrx in a report on Tuesday, July 23rd. They set a “market perform” rating for the company.
View Our Latest Report on Inhibrx
About Inhibrx
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Recommended Stories
- Five stocks we like better than Inhibrx
- How to Calculate Return on Investment (ROI)
- 3 Small Cap Stocks That Insiders Are Buying
- Why Are Stock Sectors Important to Successful Investing?
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.